TY  - JOUR
AU  - Garcia-Gutierrez, Valentin
AU  - Luna, Alejandro
AU  - Alonso-Dominguez, Juan M
AU  - Estrada, Natalia
AU  - Boque, Concepcion
AU  - Xicoy, Blanca
AU  - Giraldo, Pilar
AU  - Angona, Anna
AU  - Alvarez-Larran, Alberto
AU  - Sanchez-Guijo, Fermin
AU  - Ramirez, Maria Jose
AU  - Mora, Elvira
AU  - Velez, Patricia
AU  - Rosell, Ana
AU  - Colorado-Araujo, Mercedes
AU  - Cuevas, Beatriz
AU  - Sagües, Miguel
AU  - Cortes, Montserrat
AU  - Perez-Encinas, Manuel 
AU  - Casado Montero, Luis Felipe
AU  - Moreno-Vega, Melania
AU  - Serrano, Luis
AU  - Gomez, Valle
AU  - Garcia-Hernandez, Carmen
AU  - Lakhwani, Sunil
AU  - Paz-Coll, Antonio
AU  - de-Paz, Raquel
AU  - Suarez-Varela, Sara
AU  - Fernandez-Ruiz, Andres
AU  - Perez-Lopez, Raul
AU  - Ortiz-Fernandez, Almudena
AU  - Jimenez-Velasco, Antonio
AU  - Steegmann-Olmedillas, Juan Luis
AU  - Hernandez-Boluda, Juan Carlos
PY  - 2021
DO  - 10.1038/s41408-021-00420-8
UR  - http://hdl.handle.net/10668/17137
T2  - Blood cancer journal
AB  - Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed...
LA  - en
PB  - Nature Publishing Group
KW  - Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - Treatment Outcome
KW  - Young Adult
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Female
KW  - Fusion Proteins, bcr-abl
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Male
KW  - Middle Aged
KW  - Niacinamide
TI  - Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
TY  - research article
VL  - 11
ER  -